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SIRT3 is a member of the Sirtuin family of NAD+-
dependent deacylases and plays a critical role in
metabolic regulation. Organism-wide SIRT3 loss
manifests in metabolic alterations; however, the
coordinating role of SIRT3 among metabolically
distinct tissues is unknown. Using multi-tissue quan-
titative proteomics comparing fasted wild-type mice
to mice lacking SIRT3, innovative bioinformatic
analysis, and biochemical validation, we provide a
comprehensive view of mitochondrial acetylation
and SIRT3 function. We find SIRT3 regulates the
acetyl-proteome in core mitochondrial processes
common to brain, heart, kidney, liver, and skeletal
muscle, but differentially regulates metabolic path-
ways in fuel-producing and fuel-utilizing tissues.
We propose an additional maintenance function for
SIRT3 in liver and kidney where SIRT3 expression is
elevated to reduce the acetate load on mitochondrial
proteins. We provide evidence that SIRT3 impacts
ketone body utilization in the brain and reveal a
pivotal role for SIRT3 in the coordination between tis-
sues required for metabolic homeostasis.
INTRODUCTION
Mammals must maintain whole-body homeostasis with incon-
sistent fuel intake and have developed mechanisms to manage
times of fuel deprivation. The production, utilization, and storage
of carbohydrates, fatty acids, and protein are regulated in a tis-
sue-dependent manner, as each organ has unique functions,
metabolic pathways, and accessibility to fuel sources. Most
tissues exhibit metabolic flexibility and are capable of using
multiple types of fuels in response to shifts in nutrient availability.
The regulation of fuel switching occurs at both the cellular and
organismal level, and requires tissues to respond in concert toCmetabolic signals to maintain proper function (Stipanuk and
Caudill, 2013). As the mitochondria are the energy production
centers of the cell, mitochondrial metabolism is vital in the
adaptation to alterations in nutrient supply.
Protein acetylation is a post-translational modification (PTM)
enriched in the mitochondria of multiple tissue types and is
involved in numerous cellular processes through regulation of
protein interactions, activity, and localization (Choudhary et al.,
2009; Lundby et al., 2012). Mass spectrometry (MS)-based
proteomics has identified over 2,500 unique acetyl sites in the
mitochondria, a majority of which reside on metabolic enzymes
(Choudhary et al., 2009; Hebert et al., 2013; Still et al., 2013).
Much of our knowledge on mitochondrial protein acetylation
comes from studies on the role of the NAD+-dependent deacety-
lase Sirtuin 3 (SIRT3) in liver mitochondria (Hebert et al., 2013;
Rardin et al., 2013). In the liver, SIRT3 regulates mitochondrial
function and specificallymodulates enzymatic activity of proteins
involved in fatty acid oxidation, oxidative phosphorylation, ke-
tonebody synthesis, and the urea cycle (Hebert et al., 2013;New-
man et al., 2012). Additionally, SIRT3 is thought to play a key role
in regulating the production of reactive oxygen species (Newman
et al., 2012). SIRT3 is proposed to facilitate catabolism of fatty
acids in the liver and the peripheral use of acetate during fasting
(He et al., 2012; Jing et al., 2013). However, molecular details of
the role of SIRT3 in extra-hepatic tissues and in managing coor-
dinatedwhole-body responses to fuel availability remain unclear.
To assess the role of SIRT3 across tissues and identify tissue-
specific SIRT3 substrates and regulated biological pathways, we
employed a quantitative acetyl-proteomic method (Hebert et al.,
2013) to study SIRT3 in five tissues (brain, heart, kidney, liver,
and skeletal muscle) from fasted mice that were wild-type (WT)
or lacking SIRT3 (Sirt3/). We provide a comprehensive multi-
tissue quantitative acetyl-proteome analysis comparing multiple
biological conditions. We identified 6,286 acetyl sites on 1,172
proteins of which nearly 4,000 sites were localized to mito-
chondrial proteins, providing a compendium of acetyl sites that
are dynamically altered by SIRT3 in tissues that, until now,
remained unexplored with respect to the function of SIRT3.
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Figure 1. Quantitative Mapping of Dynamic Acetylation in Multiple Tissues
(A) Wild-type and Sirt3/ mouse brain, heart, kidney, liver, and skeletal muscle were compared in biological triplicate. Tissues were disrupted by bead milling,
and extracts were digested. Peptides were labeled with TMT reagents, combined, and fractionated by strong cation exchange chromatography. Acetyl peptides
were enriched by immunoprecipitation and analyzed via nano-RPLC MS/MS on an Orbitrap Fusion.
(B) Percentage of mitochondrial acetyl sites changing R 2-fold in the Sirt3/ condition for each tissue. Calculated as number of mitochondrial acetyl sites
changingR 2-fold per total number of quantified mitochondrial acetyl sites found in that tissue.
(C) Venn diagram displaying overlapping acetyl sites between tissues.
See also Figure S1 and Tables S1 and S2.was developed and employed, allowing for an assessment of
pathways regulated by acetylation and SIRT3. Bioinformatics
analyses of our proteome data reveal fuel-producing (liver and
kidney) and fuel-utilizing tissues (brain, heart, skeletal muscle)
display unique, SIRT3-dependent alterations in their acetyl pro-
teome, but also indicate SIRT3 regulates acetylation of proteins
involved in common core mitochondrial processes among
diverse tissues. We provide biochemical evidence that SIRT3
is required for utilization of ketone bodies to form acetyl-CoA
in extra-hepatic tissues. We establish critical tissue-dependent
roles for SIRT3 and reveal SIRT3 dictates multi-tissue coupling
required for metabolic adaptation to nutrient availability.
RESULTS
Acetyl-Proteomics Quantifies Site-Specific Changes in
Acetylation fromMultiple Tissues inMice Lacking SIRT3
We applied our quantitative acetyl-proteomic method to study
the tissue-specific and SIRT3-dependent alterations in theTable 1. Acetyl-Proteomic Metrics for Each Tissue
Tissue Brain Heart
Acetyl sites 1,247 (465) 1,159 (554
Mitochondrial acetyl sites 715 (339) 897 (499)
Acetyl proteins 523 338
Mitochondrial acetyl proteins 220 230
Total proteins 6,783 3,439
Mitochondrial proteins 685 646
Acetyl sites per protein 2.39 3.43
Acetyl sites with statistically significant fold changes (p% 0.1, Student’s t tes
of acetyl sites. Mitochondrial proteins categorized by inclusion in the MitoC
638 Cell Metabolism 21, 637–646, April 7, 2015 ª2015 Elsevier Inc.proteome and acetylome (Figure 1A) (Hebert et al., 2013). Three
5-month-old WT and three germline Sirt3/ mice were sub-
jected to a 24-hr fast beginning the morning prior to tissue
harvest. To minimize compensatory or secondary mechanisms
that occur as mice age, we selected young mice to reveal
primary tissue-specific biochemical alterations in the acetyl-
proteome that have not yet manifested as an overt phenotype.
We compared, in biological triplicate, the whole brain, heart,
kidney, liver, and skeletal muscle proteome and acetyl-
proteome in two conditions: WT and Sirt3/ (Figure 1A). We
detected 6,286 acetyl sites and quantified 5,199 acetylation
sites in five tissues (Tables 1 and S1). Nearly half of the quan-
tified acetyl sites (2,247) were localized on mitochondrial pro-
teins (Pagliarini et al., 2008), achieving deep quantification of
the mitochondrial proteome (668 proteins) (Table 1). To confirm
differences in acetylation are due to increased acetylation,
rather than a result of increased protein abundance, we
analyzed the un-modified proteome of each tissue (Table S2).
Acetyl reporter ion intensities were corrected for proteinKidney Liver Muscle
) 1,370 (317) 2,117 (578) 393 (74)
908 (255) 1,400 (494) 207 (72)
500 647 152
268 331 90
3,977 4,542 2,290
640 671 457
2.74 3.28 2.59
t) between Sirt3/ andWT are listed in parentheses next to total number
arta inventory (Pagliarini et al., 2008).
Figure 2. SIRT3 Expression Varies between Tissues and Corre-
sponds to Tissue Acetylome Alterations
(A) PRM mass spectrometry and TMT quantitation were employed to assess
SIRT3 protein expression in each of the five tissues studied. TMT-labeled pep-
tides from one WT animal from each tissue were compared in a single targeted
MS experiment. Spectra from a represented peptide ASGIPASK with reporter
ion magnification and protein fold change are presented for each tissue.
(B) A comparison of SIRT3 expression level (x axis) with percentage of mito-
chondrial sites changing R 2-fold in response to Sirt3/ (y1) and mitochon-
drial acetyl sites per the number of mitochondrial proteins identified in that
tissue (y2).
See also Figure S2.amount in each condition, and used to calculate a protein-
normalized fold change between Sirt3/ and WT (Table S1).
Of the acetyl sites quantified, 38% (1,990 acetyl sites) exhibited
a statistically significant change (p % 0.1, Student’s t test) in
acetyl occupancy in mice lacking SIRT3. Our experimental
approach analyzed the acetyl proteome and proteome of the
entire tissue, allowing for an assessment of the potential effects
of SIRT3 on acetylation outside of the mitochondria. An anal-
ysis of the distribution in fold change of acetyl sites between
the Sirt3/ and WT animals reveals a normal distribution for
both mitochondrial and non-mitochondrial populations and a
marked shift toward hyperacetylation of mitochondrial acetyl
sites when compared to non-mitochondrial acetyl sites (Fig-
ure S1A). There has been some debate on the role of SIRT3
outside of the mitochondria (Iwahara et al., 2012); however, in
the tissues tested, our study indicates the primary deacetylase
activity of SIRT3 resides in the mitochondria. As previously
reported for the liver (Hebert et al., 2013), SIRT3 does not
considerably alter the mitochondrial or non-mitochondrial
proteome; thus, changes in mitochondrial function are due pri-
marily to alterations in acetylation, and not protein abundance
(Figure S1B).CThe percent of mitochondrial acetyl sites changing greater
than 2-fold in mice lacking SIRT3 was calculated (Figure 1B).
As SIRT3 is the only established mitochondrial deacetylase,
hyperacetylated lysine residues in Sirt3/ mice are probable
SIRT3 targets. The effect of SIRT3 on mitochondrial acetylation
varies in a tissue-specific manner, with brain, heart, and muscle
displaying the greatest percentage (33%) of acetyl isoforms
increasing greater than 2-fold in the Sirt3/ condition (Table
S1; Figure 1B). Interestingly, liver and kidney contain the highest
total number of mitochondrial acetyl sites (Table 1), but a lower
percentage of acetyl sites that exhibit greater than 2-fold
increases in acetylation in Sirt3/. Liver and kidney contain a
number of acetyl sites that change less dramatically (between
1- and 2-fold) in the absence of SIRT3. To determine how differ-
ences in SIRT3 protein expression across tissues dictate acety-
lation changes during fasting, we measured SIRT3 protein
abundance by targeted MS using WT samples. Peptides from
the brain, heart, kidney, liver, and skeletal muscle of one WT
mouse were labeled with tandem mass tags (TMTs, Pierce)
and combined in equal ratios. Parallel reaction monitoring
(PRM) (Peterson et al., 2012) was performed to detect a single,
unique peptide for SIRT3 (ASGIPASK, amino acids 171–178).
The relative TMT intensities for each tissue were normalized to
total intensity across the TMT channel and plotted (Figure 2A)
and confirmed by western blotting of samples from three WT
study animals (Figure S2). Liver and kidney have the highest
protein expression levels of SIRT3, followed by brain, heart,
and skeletal muscle, comparable to previous literature reports
(Lombard et al., 2007; Shi et al., 2005).
Interestingly, the tissues with the highest levels of SIRT3
protein (liver and kidney) exhibit the lowest percentage of
mitochondrial acetyl sites changing greater than 2-fold in the
absence of SIRT3, but the greatest number of total mitochondrial
acetyl sites identified per mitochondrial protein (Figure 2B). The
percentage of mitochondrial sites changing greater than 2-fold
was used in this analysis to provide a normalization factor for
the differences in total number of acetyl sites found per tissue.
There is a positive linear correlation between SIRT3 expression
and total number of mitochondrial acetyl sites identified in
each tissue (Figure 2B). However, when examining only sites
that are dramatically altered, changing greater than 2-fold in
Sirt3/, there is segregation between liver and kidney, and
muscle, heart, and brain (Figure 2B). Overall, in tissues with lower
SIRT3 expression (brain, heart, skeletal muscle) there are fewer,
but more dynamic, changes in acetylation after a 24-hr fast when
compared to the corresponding tissues of the Sirt3/ mice.
These results provided a rich resource to explore the tissue-
specific functions of SIRT3 in whole-body metabolism.
Tissue-Specific Patterns of Acetyl Site Distribution
To determine whether acetylated proteins could be categorized
into sub-populations based on their patterns across the five
tissues, we implemented a probabilistic clustering algorithm
based on a Gaussian mixture model (Hastie et al., 2009; Hebert
et al., 2013). The algorithm used the summed acetyl fold change
for each unique UniProt identifier and generated five clusters
(Figure 3A) that segregate into two main groups: (1) acetylated
proteins regulated by SIRT3 that exhibit hyperacetylation in
SIRT3-null mice and (2) proteins with minimal perturbations inell Metabolism 21, 637–646, April 7, 2015 ª2015 Elsevier Inc. 639
Figure 3. Tissue-Specific Patterns of Acetylated Proteins and Tissue Correlation Analysis
(A) Cluster analysis of acetyl-proteins identified five clusters that define two groups based on their overall trends between Sirt3/ and WT. Acetyl-proteins are
color-coded according to their normalized fold change between Sirt3/ and WT with cluster separations denoted by black lines. Each row represents a tissue,
and each column represents an acetylated protein. Red, increased acetylation; blue, decreased acetylation; gray, not identified. Pathway analysis, number of
acetyl-proteins, and p values for enrichment are shown for two main groups of acetyl-proteins.
(B) Normalized acetyl fold changes plotted for sites found in common between any two tissues. Scatter plots on the left side of the diagonal with the number of
sites quantified and plotted in the lower right-hand corner. Axes scales are equivalent for each scatter plot. Corresponding Pearson correlation coefficients are
indicated on the right side of the diagonal. Tissues with acetyl sites behaving more similarly in response to Sirt3/ are more highly correlated and are a darker
shade of blue.
See also Figure S3.acetylation due to SIRT3. We postulated that these two groups
might represent functionally distinct proteins. An interrogation
of the sub-cellular localization of proteins found in these groups
using the functional annotation tool DAVID (Huang et al., 2009a,
2009b) against a background of all acetyl-proteins used in the
clustering analysis revealed group 1 proteins are enriched for
mitochondrial proteins (p = 1.10 3 1038, Benjamini corrected),
while group 2 proteins are dispersed throughout the cell
(nucleus, p = 2.70 3 108; intracellular non-membrane-bound
organelle, p = 1.80 3 106). Acetyl-proteins in group 1 are
significantly enriched in metabolic processes (p = 2.20 3 105)
in the mitochondria including carboxylic acid, fatty acid, ketone
body, and acetyl-CoA metabolic processes, as well as the
electron transport chain (p = 1.20 3 104). Group 2 proteins
are enriched in regulation of biological processes (p = 5.20 3
107) and are not enriched in mitochondrial pathways. These
results indicate group 1 proteins comprise potential SIRT3
targets.
We also observed patterns between tissues within the clusters
(Figure 2A). To determine tissue similarities of proteins whose
acetylation is regulated by SIRT3, we performed Euclidean dis-
tance hierarchical clustering on each cluster using an algorithm
that was adapted to take into consideration missing data values
resulting from incomplete overlap of acetyl sites and proteins
(Figure 1C) across all five tissues. Tree diagrams displaying
tissue similarities are presented in Figure S3. Functionally similar
tissues, like liver and kidney, and muscle and heart, are more
closely related to each other in every cluster of acetyl-proteins640 Cell Metabolism 21, 637–646, April 7, 2015 ª2015 Elsevier Inc.(Figure S3). The segregation of fuel-utilizing (brain, heart, muscle)
and fuel-producing tissues (liver and kidney) in the Sirt3/
condition suggest SIRT3 regulates protein acetylation in a pro-
tein- and organ-dependent manner.
We predicted that acetyl sites would also display tissue simi-
larities and would further reveal tissue-dependent response to
a loss of SIRT3 expression. To assess tissue similarities at the
acetyl site level, normalized acetyl fold changes for sites found
in common between any two tissues were plotted (Figure 3B).
The Pearson correlation coefficient was calculated and is
presented on the right side of the diagonal of the scatter plots
in Figure 3B. The greater the Pearson correlation coefficient,
the more similar acetyl sites are changing due to SIRT3 in any
two tissues. Tissue similarities emerge that are consistent with
our protein level clustering analysis, with heart, brain, and mus-
cle more similar to each other than liver and kidney.
Pathway Analysis Tool Identifies Biological Pathways
Regulated by Acetylation and SIRT3
The adaptation to diet and nutrient availability requires a coordi-
nated change in mitochondrial metabolism. These metabolic
shifts are tissue specific, but require exquisite coupling of tissues
to allow for fuel switching and metabolic homeostasis. The
extent to which SIRT3 regulates divergent pathways of nutrient
utilization and mediates metabolic coupling to respond to fuel
availability is unknown. To identify biological pathways and
understand the tissue-specific functions of SIRT3-controlled
acetyl sites, we developed and applied a biological pathway
Figure 4. Pathway Enrichment Analysis Tool Identifies Biological
Pathways Regulated by SIRT3
(A) QSSA performed with all quantified acetyl sites identifies high-scoring
biological pathways enriched with acetyl sites and controlled by SIRT3.
Canalysis we termed quantitative site set functional score analysis
(QSSA).
Enrichment analysis based on gene ontologies is a steadfast
companion in determining the biological significance of a
particular physiological perturbation and is used to generate
hypotheses on the functional relevance of the observed data.
Most established enrichment methods were developed for
gene expression data and later applied to proteomics data.
Therefore the information contained in typical over-representa-
tion analysis and newer approaches such as gene set enrich-
ment analysis (GSEA) is gene-product centric (Irizarry et al.,
2009). Using available methods with quantitative PTM data ne-
cessitates discarding site-specific modification information.
Over-representation analysis, where an arbitrary cutoff often
based on fold change is established, entails further discarding
the magnitude of the effect and all information about proteins
that fall below the cutoff. GSEA and its derivatives offer an
improvement in that they allow for the incorporation of protein
fold changes and inclusion of an entire proteomic dataset in
assigning significance to each set of genes, but are still inca-
pable of accounting for the wealth of quantitative MS data
on PTMs. QSSA shifts the focus of the enrichment analysis
from sets of genes to sets of PTM sites. We start from the
same pre-determined categories of genes used in previous
approaches (Gene Ontology, Kyoto Encyclopedia of Genes
and Genomes [KEGG] [Kanehisa and Goto, 2000], Reactome,
etc.) and incorporate site-specific data by integrating protein
sequence data from the UniProt database. QSSA is not a
rigorous method for determining the statistical significance of
enrichment, but in accordance with the exploratory nature of
proteome-wide datasets, is a tailored approach incorporating
the most salient factors in quantitative PTM data to facilitate
generation of biological hypotheses. Our method is broadly
applicable to diverse PTM datasets, including quantitative
phospho-proteomics, and the scoring algorithm is not limited
to the KEGG database. Any well-annotated gene ontology or
molecular function database could be employed.
Since our focus is lysine acetylation, we consider each
pathway background as the set of lysines contained in proteins
identified in our proteomics analysis belonging to a gene
category. Acetylation may be important to the function of a
biological process through the dynamic acetylation of multiple
weakly regulated sites on a protein or through the regulation
of one keystone site. To account for both of these possibilities,
we assessed the acetyl coverage of a pathway and the fold
change in acetylation of each acetyl site in the Sirt3/ condi-
tion (Table S1). To identify biological pathways that may be
differentially regulated by SIRT3, QSSA (described in detail
in the Supplemental Information) was performed to calculate
a standard score for each KEGG pathway, with higher
scores representing pathways likely regulated by acetylation
(Figure 4).Hierarchical clustering groups biological pathways between fuel-utilizing and
fuel-producing tissues. Dark blue, highly scoring pathway likely regulated by
SIRT3; light blue, low-scoring pathway.
(B) High-scoring KEGG pathways are listed with their corresponding scores
color-coded according to scale.
See also Figure S4.
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Biological pathway analysis indicated SIRT3 and acetylation
regulate core mitochondrial pathways common to most tissues
studied andpathways specific to individual or groupsofmetabol-
ically similar tissues. Fundamental mitochondrial processes,
including oxidative phosphorylation, the citrate cycle, and fatty
acid metabolism, are enriched with acetyl sites sensitive to
SIRT3 expression in brain, heart, kidney, liver, and skeletal mus-
cle (Figure 4A). These core pathways are essential for cellular
function and represent common regulatory targets of SIRT3
across tissues. In support of this observation, of the 87 acetyl
sites found in all tissues (Figure S4A), nearly half are members
of core mitochondrial pathways. These include multiple subunits
of ATP synthase, complexes I and II of the electron transport
chain, and numerous enzymes of the citrate cycle (citrate
synthase, malate dehydrogenase, aconitase, succinate dehy-
drogenase, and isocitrate dehydrogenase). To illustrate the utility
of the QSSA method, we directly compared KEGG pathway
enrichment scores from QSSA with KEGG pathway fold enrich-
ment scores from the commonly used functional annotation
tool DAVID (Huang et al., 2009a, 2009b) (Figure S4B). Validating
the general applicability of QSSA, a number of high-scoring
QSSA pathways were also identified in the DAVID analysis,
including the citrate cycle and branched-chain amino acid
catabolism (Figure S4B). A side-by-side comparison of the
scores provided for each pathway (Figure S4B) reveals that
QSSA provides information on the extent of enrichment for
many pathways for which DAVID provides no information, thus
providing a more nuanced and fine-grained hypothesis-gener-
ating tool for quantitativeMS-basedPTManalysis. In fact, ketone
body synthesis and utilization, a pathway for which we present
detailed biochemical follow-up in the brain, was not identified
as enriched using DAVID.
Mitochondrial metabolism must also be regulated in a tissue-
dependent manner to allow for metabolic flexibility. In response
to a fast, fuel-producing pathways, such as fatty acid oxidation
and ketone body generation, must be upregulated in hepatic
tissues, while fuel-utilizing pathways, like acetyl-CoA production
for the citrate cycle, are necessary in extra-hepatic tissues.
To determine whether SIRT3 regulated biological processes in
a tissue-dependent manner, calculated pathway scores were
visualized by Euclidean distance hierarchical clustering (Fig-
ure 4A), identifying segregation in pathway-scoring patterns
between fuel-utilizing and fuel-producing tissues. We find a
number of SIRT3-regulated pathways in brain, heart, and skel-
etal muscle that promote alternative fuel utilization, including
degradation of short chain carbon molecules (propanoate
and butanoate metabolism) andmetabolism of amino acids (Fig-
ure 4B). Skeletal muscle is a predominant location for branched-
chain amino acid catabolism, providing succinyl-CoA for the
citrate cycle and alanine that is shuttled to the liver to provide
carbon for gluconeogenesis (Suryawan et al., 1998). Both
branched-chain amino acid degradation in the skeletal muscle
and alanine metabolism in the liver and skeletal muscle were
identified as probable metabolic pathways controlled by
SIRT3, suggesting SIRT3 may be an important regulator of the
glucose-alanine cycle during fasting metabolism. During fasting,
another essential metabolic transition is the generation of ketone
bodies by the liver and their utilization as an alternative fuel
source by extra-hepatic tissues. Ketone body synthesis and uti-642 Cell Metabolism 21, 637–646, April 7, 2015 ª2015 Elsevier Inc.lization was identified as one of the highest candidate SIRT3-
controlled pathways in brain, heart, skeletal muscle, and liver
(Figure 4B). SIRT3 is known to regulate ketone body production
in the liver through the deacetylation and activation of hydroxy-
methylglutaryl-CoA synthase 2 (HMGCS2) (Hirschey et al.,
2010; Shimazu et al., 2010); however, whether SIRT3 mediates
ketone body utilization in extra-hepatic tissues was unclear.
SIRT3 Mediates Cross-Tissue Coupling for Ketone Body
Synthesis and Degradation
To provide evidence that SIRT3 differentially affects ketone body
metabolism in hepatic and extra-hepatic tissues, we determined
acetoacetate utilization and acetyl-CoA generation in the brain.
This was accomplished by monitoring acetoacetate-dependent
acetyl-CoA production in homogenates of brain cortices of
8-month-old WT and Sirt3/ mice that were fasted for 24 hr.
The brain is an extra-hepatic tissue that relies solely on glucose
and ketone bodies during a fast; therefore, the brain serves as
the model tissue to study the effects of SIRT3-controlled protein
acetylation on ketone body degradation. Using brain cortex
homogenate from fasted WT or Sirt3/ mice and quantitative
LC-MS-based analysis, we monitored the production of acetyl-
CoA from the addition of the ketone body acetoacetate (Figures
5A and S5). Succinyl-CoA and CoAwere included in the reaction
to ensure that flux through the pathway was not initially limited
by the presence of required co-substrates. We find a 3-fold
decrease in acetoacetate-dependent acetyl-CoA production in
Sirt3/ brain cortex homogenates at low succinyl-CoA levels
(Figure 5A), suggestive of a defect in acetyl-CoA production
through the ketone body utilization pathway in mice lacking
SIRT3 (Figure 5C). We performed a targeted LC-MS-based
metabolite analysis on WT and Sirt3/ brain. Consistent with
an alteration in ketone body utilization, a slight decrease in
whole-cell acetyl-CoA was measured in the Sirt3/ condition
(Figure 5B). Although this trend did not reach statistical signifi-
cance, the observation is similar to our previously published
report that acetyl-CoA levels were lower in liver of Sirt3/
mice compared to WT (Hebert et al., 2013). The observation
that reduced activity in ketone body utilization presented in Fig-
ure 5A is more dramatic than the slight reduction in whole-tissue
acetyl-CoA levels (Figure 5B) is not surprising and suggests
that other compensating activities, including amino acid or
fatty acid metabolism, reduction in acetyl-CoA-consuming pro-
cesses, or other non-mitochondrial metabolic processes may
prevent cellular acetyl-CoA from further depletion.
To confirm defects in ketone body generation in hepatic
tissues, we measured a ketogenesis reaction in liver homoge-
nates of WT and Sirt3/ mice by monitoring the rate of acetyl-
CoA-dependent CoA formation by LC-MS. In support of the
hypothesis that SIRT3 is involved in tissue-specific fuel switch-
ing, we find a decrease in the activity of a ketogenesis pathway
in Sirt3/ liver (Figure S5). Consistent with our results, previous
metabolomics analyses in plasma and liver identified alterations
in the ketone body 3-hydroxybutyrate during fasting and in hy-
droxybutyryl carnitine levels (Hallows et al., 2011; Hirschey
et al., 2010; Shimazu et al., 2010) in mice lacking SIRT3.
Acetyl-CoA generated through ketone body degradation is
combined with oxaloacetate to form citrate by the enzyme
citrate synthase, entering the citrate cycle to provide reducing
Figure 5. SIRT3 Mediates Cross-Tissue Link for Ketone Body
Production and Utilization
(A) Average rate of acetoacetate-dependent acetyl-CoA production in brain
cortex homogenates from fourWT (gray) or four Sirt3/ (blue) mice indicates a
defect in acetyl-CoA production in Sirt3/ at low succinyl-CoA concentra-
tions. Error bars represent SD (* indicates statistical significance, p < 0.05,
Student’s t test).
(B) Targeted metabolite analysis of WT and Sirt3/ brain cortex (15-month-
old, n = 4 per condition) identifies altered energetic status in Sirt3/ brain.
(C) A model for the differential regulation of ketone body production and
utilization by SIRT3 in hepatic and extra-hepatic tissues. In the liver, SIRT3 is
required for the synthesis of the ketone bodies acetoacetate and 3-hydrox-
ybutyrate, through regulation of HMGCS2 enzymatic activity and pathways
that generate acetyl-CoA in response to nutrient deprivation. This counters
the role of SIRT3 in the brain, where SIRT3 is necessary for the utilization of
acetoacetate to form acetyl-CoA to be used for energy production.
See also Figures S5 and S6.equivalents required for adenosine triphosphate (ATP) produc-
tion. In a separate reaction, we monitored citrate synthase activ-
ity by combining cortex homogenate with oxaloacetate and
acetyl-CoA and measuring citrate formation over time to deter-
mine whether decreased acetyl-CoA production in the Sirt3/
condition was due to accelerated utilization of acetyl-CoA by
citrate synthase (Figure S5). This was not the case; in fact, we de-
tected a decrease in oxaloacetate-dependent citrate formationCin Sirt3/, which is consistent with prior results suggesting
citrate synthase is also a target of SIRT3 (Hebert et al., 2013).
However, we cannot rule out the possibility that acetyl-CoA or
another co-substrate, like succinyl-CoA, is consumed by an un-
defined metabolic pathway in the Sirt3/ condition and com-
petes with the assayed activity.
Taken together, the decrease in acetoacetate-dependent
generation of acetyl-CoA at low succinyl-CoA concentrations
represents a deficiency in ketone body utilization in the brain
of mice lacking SIRT3, supporting a critical role for SIRT3
in this pathway. Consistent with the metabolite flux analysis,
two central enzymes in acetyl-CoA production are highly prob-
able targets for SIRT3 regulation: succinyl-CoA:3-ketoacid-
CoA transferase (OXCT) and acetyl-CoA acetyltransferase 1
(ACAT1). OXCT transfers the CoA from succinate to acetoace-
tate, forming acetoacetyl-CoA that is then converted by ACAT1
to two molecules of acetyl-CoA. Both enzymes are hyperacety-
lated in the brain ofSirt3/ animals (Figure 5C; Table S1). Impor-
tantly, OXCT is only expressed in extra-hepatic tissues to avoid
non-productive cycling of acetoacetate in the liver and is
exclusively acetylated in the brain (five acetyl sites) and heart
(three acetyl sites) in this analysis. Our previous report on
ACAT1 enzymatic function identified a defect in catalysis of
acetyl-CoA formation due to acetylation of K260 and K265 (Still
et al., 2013), providing direct enzymatic evidence that supports
our current findings. Numerous acetyl sites, including K260
and K265, were identified in all tissues in this study (Table S1).
The observation that the magnitude of the defects in acetoace-
tate-dependent acetyl-CoA production were dependent on
succinyl-CoA levels (Figure 5A) suggested that hyperacetylation
of OXCT decreased catalytic efficiency, likely by affecting the
Vmax/Km kinetic parameter for succinyl-CoA. Consistent with
this observation, lysine 451 (K451), a site identified and quanti-
fied only in the brain, displays the largest magnitude acetyl fold
change (67% increase, p = 1.1 3 104, Student’s t test) in the
Sirt3/ condition, when compared to other acetyl sites quanti-
fied on OXCT. This acetyl residue lies within the CoA binding
pocket of OXCT (PDB 3OXO), approximately 4 A˚ from the ribo-
syl-phosphate group of CoA, thus acetylation of this site would
be predicted to disrupt the binding or orientation of succinyl-
CoA and serve as a mechanism for regulating OXCT function.
To provide in vitro evidence for the effect of acetylation, we per-
formed a biochemical analysis of recombinant OXCT, demon-
strating that acetylation of K451 resulted in low catalytic activity
that could be rescued in part by pre-incubation with SIRT3
(Figure S6). Using site-specific incorporation of acetyllysine,
we expressed and purified recombinant OXCT that is fully
acetylated at K451 (Neumann et al., 2009). In vitro OXCT activity
assays across several concentrations of succinyl-CoA were
performed and revealed that SIRT3 induced a 2.5-fold increase
in the catalytic activity of acetylated OXCT (Figure S6). Minimal
changes in activity were observed with identically treated WT
OXCT (data not shown). We note that upon expression and
purification, acetylated OXCT displayed extremely low activity
and likely formed an oligomeric structure that partially occluded
the acetyl site. This necessitated limited proteolysis of acety-
lated OXCT to demonstrate that SIRT3 was capable of removing
the acetyl mark, as indicated by LC-MS measurement of the
reaction product O-acetyl-ADP-ribose (Figure S6).ell Metabolism 21, 637–646, April 7, 2015 ª2015 Elsevier Inc. 643
The end product of ketone body utilization, acetyl-CoA, is the
oxidation substrate for the citrate cycle, a critical pathway for
energy generation in the mitochondria. To determine whether
the deficiency in ketone body utilization in the brain and the
alteration in mitochondrial acetylation manifest in an overt
energetic state or redox state, we performed a targeted
LC-MS-based metabolite analysis on brain cortex of WT and
Sirt3/ mice (Figure 5B). We observed a significant decrease
of GSH/GSSG and glutathione in Sirt3/ mice, consistent with
prior studies showing that SIRT3 loss leads to increased reactive
oxygen species production and oxidative stress (Someya et al.,
2010), indicating that our current biological analysis reflects es-
tablished phenotypes of SIRT3 knockout. Chemically, cellular
energy is mainly produced in the form of two triphosphate com-
pounds, GTP, which is directly formed in the citrate cycle by
succinyl-CoA synthetase, and ATP, produced by oxidative phos-
phorylation. The high-energy cofactors, GTP and ATP, showed
approximately a 50% and 20% decrease in the brains of mice
lacking SIRT3 (Figure 5B), respectively, with the change in GTP
being statistically significant. Collectively, these data are consis-
tent with a defect in the ability of Sirt3/ mice to switch fuel
under a prolonged fast, including decreased ketone body gener-
ation in the liver and reduced ketone body utilization in extra-
hepatic tissues such as brain. The magnitude of decreased
ATP and acetyl-CoA levels in the Sirt3/ brain may be indicative
of organism-wide compensatory mechanisms that act to main-
tain metabolic and energetic homeostasis. This study reveals
multi-tissue homeostatic effects and captures early-stage
biochemical dysregulation within five individual tissues resulting
from whole-body loss of SIRT3 expression.
DISCUSSION
Through the regulation of protein acetylation, SIRT3 controls
enzymatic activity and flux of numerous metabolic pathways.
Our study provides evidence that SIRT3 possesses (1) common
core functions in all tissues through the regulation of pathways
like the citrate cycle and oxidative phosphorylation, (2) tissue-
specific functions to allow for crosstalk between tissues that
enables a response to nutrient shifts (e.g., ketone body genera-
tion in the liver and utilization in the brain), and (3) an additional
maintenance function to minimize the effects of untargeted
acetylation in energy-producing tissues (liver and kidney) where
higher SIRT3 expression reflects the acetate burden of each
tissue.
The effect of SIRT3 on mitochondrial acetylation varies in a
tissue-specific manner. Brain, heart, and skeletal muscle exhibit
a greater percentage of sites hyperacetylated (> 23) in SIRT3
knockout mice, while liver and kidney contain the highest total
number of mitochondrial acetyl sites, but a lower percentage of
dynamic acetyl sites (Figure 2). In this 24-hr fasted phase, extra-
hepatic tissues rely on fatty acids and ketone bodies produced
by increased fatty acid oxidation in the liver (Bauer et al., 2004).
Brain, heart, and skeletal muscle must efficiently oxidize acetyl-
CoA for energy production, while hepatic tissues produce large
amounts of intra-mitochondrial acetyl-CoA. We propose that
this necessary demand for acetyl-CoA production drives wide-
spread protein acetylation in liver, creating a greater need for
the maintenance deacetylase functions of SIRT3.644 Cell Metabolism 21, 637–646, April 7, 2015 ª2015 Elsevier Inc.Our study and others reveal widespread acetylation of the
mitochondrial proteome (Hebert et al., 2013; Kim et al., 2006;
Still et al., 2013); however, the mechanism of acetylation is as
of yet unknown, with scarce evidence for enzymatic acetyltrans-
ferase activity residing in the mitochondria (Scott et al., 2014).
Protein acetylation might occur non-enzymatically (Tanner
et al., 2000) with the levels and extent of acetylation reflecting
acetyl-CoA concentration and conditions of the organelle
(Cai et al., 2011). The slightly elevated pH (pH 7.9) of the
mitochondrial matrix compared to the cytosol and the millimolar
intra-mitochondrial concentrations of acetyl-CoA generate
a favorable condition for non-enzymatic lysine acetylation
(Garland et al., 1965; Paik et al., 1970). Regardless, both
enzyme-catalyzed and non-enzymatic acetylation reactions are
expected to increase as acetyl-CoA increases, and therefore
the tissue-specific levels of protein acetylation might reflect
the distinct conditions of each tissue type. Moreover, it is impor-
tant to highlight that functional (targeted) acetylation and
spurious (untargeted or non-regulatory) acetylation can occur
via enzyme-catalyzed or uncatalyzed reactions. Here we sug-
gest that higher SIRT3 expression in liver and kidney is required
to remove both targeted and spurious protein acetylation that
is a consequence of the increased demand to produce acetyl-
CoA under fasting. In the brain, heart, and skeletal muscle,
acetyl-CoA is rapidly consumed for energy, leading to reduced
levels of spurious acetylation and reduced need for high levels
of SIRT3, which acts in a more targeted manner by primarily
deacetylating regulatory acetylation sites. Consistent with this
idea, acetyl-CoA concentrations in liver are estimated to be
3- to 5-fold higher compared to those in skeletal muscle and
brain (Allred and Guy, 1969; Cederblad et al., 1990; Palladino
et al., 2012).
Our study reveals that SIRT3 mediates metabolic coupling
between fuel-producing and fuel-utilizing tissues through dy-
namic acetylation of numerous mitochondrial pathways
identified with our multi-tissue mitochondrial acetylome and
innovative bioinformatics pathway analysis tool. We provide
evidence that SIRT3 promotes ketone body utilization in
the brain by deacetylating and enhancing flux through OXCT
and ACAT1, manifesting in bioeneregetic deficiencies in aged
Sirt3/ animals. While a picture is emerging for the importance
of SIRT3 in fuel switching during adaptation to altered metabolic
status, our multi-tissue, quantitative acetyl proteome com-
pendium provides a rich resource to further explore the tissue-
specific functions of SIRT3, and the comparative mitochondrial
acetylome required to understand metabolic regulation and
the etiology of human diseases associated with the inability to
perform efficient fuel switching.EXPERIMENTAL PROCEDURES
Sample Preparation, MS, and Data Analysis
Mouse brain, heart, kidney, liver, and skeletal muscle were isolated from
5-month, age-matched Sirt3/ and WT mice that were fasted for 24 hr
(9am–9am) and immediately frozen in liquid nitrogen. All animal studies were
conducted at the AAALAC-approved animal facility in the Genetics and
Biotechnology Center of the University of Wisconsin-Madison. Experiments
were performed in accordance with protocols approved by the University of
Wisconsin-Madison Institutional Animal Care and Use Committee. Samples
were suspended in lysis buffer and lysed by glass bead milling (Retsch).
Samples were denatured, reduced, alkylated, and digested with trypsin
(Promega). TMT labeling of desalted peptides was performed according to
the manufacturer’s instructions (Thermo Pierce). Labeled peptides were
fractionated by SCX chromatography, and acetylated peptides were enriched
with pan-acetyl lysine antibody-agarose conjugate. Acetyl-enriched and non-
enriched protein fractions were analyzed by online nano-reverse phase
liquid chromatography (Waters) coupled to an Orbitrap Fusion (Q-OT-qIT,
Thermo Scientific). All MS/MS data were analyzed using the Coon OMSSA
Proteomics Software Suite (COMPASS) (Wenger et al., 2011). Results were
filtered to a 1% FDR.
SIRT3 Expression
Targeted MS
Unlabeled peptide fractions from brain, heart, kidney, liver, and skeletal mus-
cle of a WT mouse were subject to TMT labeling. Following tagging, peptides
were mixed at a 1:1:1:1:1 ratio according to BCA results. For targeted MS
analysis, the Sirt3 peptide ASGIPASK (+2,m/z 594.864, aa 171–178) was iso-
lated over a 1-Th window. Results were normalized to total signal intensity for
each TMT tag.
Bioinformatics
Clustering
To reduce the overall percentage of missing values to enable clustering of
the entire dataset, missing protein abundance values were imputed for acetyl
isoforms that were identified and quantified, but lacked protein level quantita-
tion. To impute values, the average normalized intensity for all proteins found
in each tissue of each mouse was calculated. This value was then used to
calculate a protein fold change, to which the acetyl fold change could be
normalized. Acetyl site fold change values were collapsed onto protein by
taking the sum of the acetyl fold change for all acetyl sites identified and quan-
tified for a unique UniProt identifier. To cluster the protein dataset (1,100 pro-
teins in five tissues) we used a Gaussian mixture model clustering approach
(Hastie et al., 2009) with consensus clustering (Nguyen and Caruana, 2007).
Due to the large number of missing values (85% of proteins having missing
values in two or more tissues), prior to applying the clustering method, we
interpolate the missing value with the mean of the non-missing values of the
same protein. To cluster each K cluster, we used hierarchical clustering using
the Euclidean metric for distance.
QSSA
The intersection of the KEGG pathway map (Merico et al., 2010) and proteins
identified with < 1% FDR was used for the gene set background. Acetylation
coverage for each ðpÞ pathway was calculated as the number of acetyl sites
identified ðnKÞ over the total number of lysines in the pathway ðnsÞ, counted
using protein sequences from UniProt. Dynamic response to SIRT3 was taken
into account by calculating the mean magnitude fold change ðFCÞ for each
acetyl site quantified. To allow for combining acetylation coverage and fold
change, the standard score of each quantity was taken. The overall pathway
score was then calculated as the average of the individual Z scores:

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
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Tissues were clustered by hierarchical clustering by calculating Euclidean
distance and centroid linkage in Cluster 3.0 (de Hoon et al., 2004). Clusters
were visualized with Java TreeView (Saldanha, 2004). A general outline of
our code is found in accompanying text file (Data S1).
Ketone Body Utilization Activity Assay in Brain Homogenate
Brain cortices isolated from 8-month-old, 24-hr-fasted WT and Sirt3/ mice
(n = 4) were placed in ice-cold PBS supplemented with deacetylase inhibitors
(1 mM sodium butyrate, 1 mM trichostatin A) and homogenized 33 1,000 rpm
with a glass homogenizer and Teflon pestle. The sample was centrifuged twice
at 1,000 3 g for 10 min at 4C to remove insoluble material. The supernatant
was used for the activity assay, and protein concentration was determined
by BCA. To test acetoacetate utilization activity, homogenates were combined
with 1mM acetoacetate, 0.5 or 1 mM succinyl CoA, and 0.5mMCoA in PBS at
37C. A control reaction was performed without acetoacetate. Reaction time
points were taken at 1, 3, 5, 8, 10, 12, 15, and 20min by quenching the reactionCmixture in nine volumes of ice-cold methanol. Citrate synthase activity was
monitored by combining homogenates with 0.5 mM oxaloacetate and
0.5 mM acetyl-CoA in PBS at 37C. A control reaction was performed without
oxaloacetate. Reaction time points were taken at 1 and 10 min by immediately
quenching the reaction mixture in nine volumes of ice-cold methanol. All
samples were centrifuged at 21,000 3 g for 10 min, and supernatants were
diluted and further analyzed by reverse-phase separation on a Synergy
Hydro-RP column (100 mm 3 2 mm, 2.5 mm particle size, Phenomenex)
coupled by negative-mode electrospray ionization to an Orbitrap mass spec-
trometer, as previously described (Lu et al., 2010).
Sample Preparation for Metabolite Analysis in Brain
Brain cortices isolated from 15-month, 24-hr-fasted WT and Sirt3/ mice
(n = 4) were placed in 0.8 ml cold (20C) 80:20 methanol:H2O (v/v) and
homogenized 3 3 1,000 rpm with a glass homogenizer and Teflon pestle.
The sample was centrifuged at 14,000 3 g for 10 min at 4C. The supernatant
was transferred to a new tube on ice. The pellet was re-extracted with 0.5 ml
cold (20C) 80:20 methanol:H2O (v/v) twice, and the supernatants were
combined. The samples were dried under nitrogen and resuspended in H2O
for LC-MS analysis. The results were normalized to tissue weight.
Statistical Analysis
Proteomic data are expressed as log2 fold change between Sirt3/ and WT.
Statistical significance was calculated by Welch’s t test. Biochemical assay
results are expressed as mean ± SD. Statistical significance was assessed
by Student’s t test. A p value of < 0.05 was considered statistically significant
for biochemical assays. Graphs were prepared and statistical analyses were
performed using Origin, GraphPad Prism 6, Excel, or MATLAB.
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